Preliminary communicationVenlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: A randomized, parallel group, open-label trial
Introduction
The most common phenotypic expression of bipolar illness is Bipolar II (BP II) disorder. It is highly recurrent, with the majority of episodes being depressive (Dunner et al., 1976, Simpson et al., 1993, Akiskal, 2005, Akiskal and Benazzi, 2005, Berk and Dodd, 2005, Sato et al., 2005). While antidepressant use has been associated with cycle acceleration in BP I disorder (Wehr and Goodwin, 1987, Goodwin and Jamison, 1990), the presence of antidepressant-induced rapid cycling in BP II disorder has been more difficult to establish (Akiskal and Benazzi, 2005, Benazzi, 1997). To date, most reports of drug-induced cycling in BP II disorder derive from uncontrolled studies or retrospective chart reviews of mixed BP I and BP II populations (Leverich et al., 2006, Stoll et al., 1994, Altshuler et al., 1995, Goodwin and Ghaemi, 1998, Ghaemi et al., 2003, Goldberg and Truman, 2003, Ghaemi et al., 2004, Marangell et al., 2004, Truman et al., 2007, Goldberg and McElroy, 2007). For example, several naturalistic studies have found higher manic switch rates during antidepressant (20%–84%) versus combined antidepressant plus mood stabilizer (32%) therapy (Goodwin and Ghaemi, 1998, Ghaemi et al., 2003, Goldberg and Truman, 2003, Ghaemi et al., 2004). More recently, Leverich et al. (2006) reported a higher frequency of syndromal and sub-syndromal hypomanic and mixed mood conversion episodes during venlafaxine (versus sertraline or bupropion) therapy in a study of mixed BP I, BP II, BP NOS, and BP schizo-affective patients. A recent retrospective, self-report study of 332 BP patients who had previously received antidepressant therapy found that 44% reported at least 1 mood conversion episode, and patients with a history of multiple antidepressant trials have an increased likelihood of reporting mood conversions. Moreover, the risk of mood conversion was more likely in BP patients who had ever experienced a mood conversion during tricyclic antidepressant (TCA), serotonin reuptake inhibitors (SSRI), or bupropion therapy (Truman et al., 2007).
In contrast, several prospective controlled clinical trials of fluoxetine monotherapy (Amsterdam et al., 1998, Amsterdam et al., 2004, Amsterdam and Shults, 2005, Parker et al., 2006) and venlafaxine monotherapy (Amsterdam, 1998, Amsterdam and Garcia-Espana, 2000, Parker et al., 2003) of BP II major depressive episode (MDE) have found relatively low hypomanic switch rates. None of these studies, however, have specifically examined efficacy and mood conversion rates in BP II MDE patients with rapid versus non-rapid cycling disorder.
In a primary analysis examining the safety and efficacy of initial venlafaxine versus lithium monotherapy of BP II MDE, we reported that venlafaxine monotherapy produced a greater reduction in depressive symptoms versus lithium (95% CI = (− 11.97,− 1.18)) (p = 0.017) and a greater proportion of treatment responders (58.1% versus 12.5%) (p < 0.0005) and treatment remitters (44.2% versus 7.5%) (p < 0.0005). Moreover, we found no difference over time in the rate of treatment-emergent hypomanic symptoms during venlafaxine versus lithium monotherapy (Amsterdam and Shults, 2008).
In the current analysis, we present additional comparative safety and efficacy results of venlafaxine versus lithium monotherapy in rapid and non-rapid cycling patients with BP II MDE. We hypothesize that lithium may have superior efficacy to venlafaxine monotherapy with a lower mood conversion rate in the rapid cycling patients relative to the non-rapid cycling patients.
Section snippets
Subjects
Outpatients ≥ 18 years old with a DSM IV Axis I diagnosis of BP II disorder and a current diagnosis of MDE were enrolled. All had a baseline 17-item Hamilton Depression Rating (HAM-D 17) (Williams, 1988) score ≥ 18. Patients with a co-morbid DSM IV Axis I diagnosis were not specifically excluded from the trial if the co-morbid condition did not constitute the primary disorder. Patients were excluded if they had a history of mania or psychosis, substance abuse or dependence in the preceding
Enrollment
Eighty-four patients were enrolled in the trial: 48 (57%) were women and 69 (82.1%) were Caucasian. Mean (SD) age was 37.2 (13.4) years (range 18–74 years); mean age at 1st MDE was 18.7 (8.7) years (range 5–57 years); mean age at 1st hypomanic episode was 20.7 (8.2) years (range 8–57 years). Mean illness duration was 18.5 (12.0) years (range 1–55 years); mean duration of current MDE was 15.0 (19.3) months (range 0.75–90 months). The mean number of prior MDEs was 7.7 (7.2) (range 0–35); mean
Discussion
To date, there have been few studies specifically examining the relative safety and efficacy of antidepressant versus mood stabilizer monotherapy of rapid and non-rapid cycling BP II patients. Several studies have suggested that antidepressant use may cause cycle acceleration in BP II patients (Wehr and Goodwin, 1987, Goodwin and Jamison, 1990, Altshuler et al., 1995, Goodwin and Ghaemi, 1998, Montgomery et al., 2000, Ghaemi et al., 2003, Goldberg and Truman, 2003, Ghaemi et al., 2004,
Conclusion
There has been a paucity of controlled studies examining the comparative safety and efficacy of antidepressant versus mood stabilizer therapy in rapid and non-rapid cycling BP disorder. The present analysis compared venlafaxine and lithium monotherapy in rapid and non-rapid cycling patients with BP II MDE. In contrast to initial expectations of lithium superiority in rapid cycling BP II patients, venlafaxine demonstrated significantly greater efficacy versus lithium, and a similar mood
Role of funding source
This research was supported by a grant from The Stanley Medical Research Institute, and by The Jack Warsaw Fund for Research in Biological Psychiatry of the University of Pennsylvania Medial Center. Funding sources had no further involvement in study design; in the collection, analysis and interpretation of data; in writing of the report; and in the decision to submit the paper for publication.
Conflict of interest
At the time this research work was conducted, Dr. Amsterdam received support from NIMH grants 1R01MH060353, 1R34MH070753, 1R01MH060998, 1R01MH63818; from NIH/NCCAM grants 1R21AT002289 and 1R21AT001916; and from Lilly Research Laboratories, Forest Laboratories, and Organon, Inc. He was a member of the speaker's bureau of Wyeth, Inc. and Bristol-Myers-Squibb. Dr. Shults received research support from NIH grant 1R01CA096885.
References (56)
The dark side of bipolarity: detecting bipolar depression in its pleomorphic expressions
J. Affect. Disord.
(2005)- et al.
Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?
J. Affect. Disord.
(2005) - et al.
Venlafaxine monotherapy in women with bipolar II depression
J. Affect. Disord.
(2000) - et al.
Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients
J. Affect. Disord.
(2000) Prevalence of bipolar II disorder in outpatient depression. A 203-case study in private practice
J. Affect. Disord.
(1997)A different depression: clinical distinctions between bipolar and unipolar depression
J. Affect. Disord.
(2005)- et al.
Current research on rapid cycling bipolar disorder and its treatment
J. Affect. Disord.
(2001) - et al.
Pharmacotherapy of depression and mixed states in bipolar disorder
J. Affect. Disord.
(2000) - et al.
SSRIs as mood stabilizers for bipolar II disorder: a proof of concept study
J. Affect. Disord.
(2006) - et al.
Irritable psychomotor elation in depressed inpatients: a factor validation of mixed depression
J. Affect. Disord.
(2005)
Bipolar depression: pharmacotherapy and related therapeutic strategies
Biol. Psychiatry
Antidepressant-induced mania and cycle acceleration: a controversy revisited
Am. J. Psychiatry
Practice guidelines for the treatment of patients with bipolar disorder
Am. J. Psychiatry
Practice guidelines for the treatment of patients with bipolar disorder (revision)
Am. J. Psychiatry
Efficacy and safety of venlafaxine in bipolar type-II major depressive episode
J. Clin. Psychopharmacol.
Fluoxetine monotherapy for bipolar type II and bipolar NOS major depression — a double-blind, placebo-substitution, continuation study
Int. Clin. Psychopharmacol.
Efficacy and safety of fluoxetine in bipolar II major depressive episode
J. Clin. Psychopharmacol.
Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression — low manic switch rate
Bipolar Disord.
What drugs are best for bipolar depression?
Ann. Clin. Psychiatry
Bipolar II disorder: a review
Bipolar Disord.
Trends in the treatment of bipolar disorder by outpatient psychiatrists
Am. J. Psychiatry
On eliminating the asymptotic bias in the quasi-least squares estimate of the correlation parameter
J. Stat. Plan. Inference
A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder
Int. Clin. Psychopharmacol.
Clinical factors in lithium carbonate prophylaxis failure
Arch. Gen. Psychiatry
The course of development of mania in patients with recurrent depression
Am. J. Psychiatry
Treatment of bipolar disorder
J. Clin. Psychiatry
Clinical management —imipramine/placebo administration manual: NIMH treatment of depression collaborative research program
Psychopharmacol. Bull.
Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN)
Cited by (46)
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review
2022, Journal of Affective DisordersCitation Excerpt :Amsterdam et al. (2013) included patients with BII and compared those with a history of RC with those without. 167 patients recovered from a depressive episode with fluoxetine monotherapy treatment in a 12-week open-label trial (Amsterdam et al., 2009). These patients were randomly assigned to either continue fluoxetine, or stop fluoxetine and start lithium or placebo.
Cutaneous adverse drug reactions to psychotropic drugs and their risk factors – a case-control study
2019, European NeuropsychopharmacologyCitation Excerpt :CADRs appeared to occur slightly earlier than the rest of the ADRs. There have been several studies on CADRs to psychotropic drugs, especially regarding antiepileptic and antidepressant drugs (Warnock and Morris, 2002,2003; Alvestad et al., 2007; Amsterdam et al., 2009; Wang et al., 2012). In the present study, we found clomipramine, maprotiline (tricyclic antidepressants and also the overall group of antidepressants), carbamazepine and lamotrigine (and antiepileptics in general) to be positively associated with CADRs.
Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator
2018, Journal of Affective DisordersCitation Excerpt :Furthermore, Young et al. (2010) showed that BD subjects with higher blood lithium levels had worsened clinical response in bipolar depression, not even better than placebo on HAM-D scores. Regarding potential compliance issues with higher blood lithium levels, only 37.5% completed a 12-week trial with lithium monotherapy in bipolar depression under higher lithium doses (mean=966 mg/day) (Amsterdam et al., 2009; Amsterdam and Schults 2008) compared to 79.1% of completers with an antidepressant. Similarly, a previous study in bipolar depression with defined lithium levels of 0.8–1.2Meq/L showed early termination in 61% (30 out of 49) of patients (Suppes et al., 2008).
Design limitations to bipolar II treatment efficacy studies: A challenge and a revisionist strategy
2018, Journal of Affective DisordersCitation Excerpt :Table 3 provides details on measures of hypomania, with eight of the nine studies employing the YMRS, while three also employed a measure of clinical global improvement (CGI). Only two of the nine specified a period of rating, with one (Amsterdam and Shults, 2010) stating mood symptoms were assessed over the preceding treatment period at each study visit, and the other (Amsterdam et al., 2009) measured mean number of days to first rise in YMRS scores. None provided a specific strategy for rating symptoms and, again, parameters rated (i.e. severity, duration or number of hypomanic episodes) were not specified in any article.
Current Status and Treatment of Rapid Cycling Bipolar Disorder
2024, Journal of Clinical Psychopharmacology